Emergence of hepatitis B infection despite antibodies to hepatitis B surface antigen: A new nosocomial risk in patients with end-stage renal disease [3]

Transplantation

Volumn 81, Issue 9, 2006, Pages 1358-1359

  Moal, Valérie ^a   Vacher Coponat, Henri ^a   Botelho, Elisabeth ^a   Berland, Yvon ^a   Colson, Philippe ^b   Tamalet, Catherine ^b   Henry, Mireille ^b  

^a HÔPITAL DE LA CONCEPTION   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE;

ADULT; ANTIBODY DETECTION; ANTIGEN DETECTION; BLOOD TRANSFUSION; CASE REPORT; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INFECTION RISK; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LETTER; MALE; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS MUTATION;

ANTIBODIES, VIRAL; CROSS INFECTION; FRANCE; HEPATITIS B; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RISK FACTORS;

EID: 33744501257     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000202731.01530.cb     Document Type: Letter

References (6)

1. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 1997; 4(suppl 1): 11.
2. Carman WF, Trautwein C, Van Deursen FJ, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology 1996; 24: 489.
3. Wallace LA, Echevarria JE, Echevarria JM, et al. Molecular characterization of envelope antigenic variants of hepatitis B virus from Spain. J Infect Dis 1994; 170(5): 1300.
4. Ashton-Rickardt PG, Murray K. Mutants of the hepatitis B virus surface antigen that define some antigenically essential residues in the immunodominant a region. J Med Virol 1989; 29(3): 196.
5. Carman WF, Korula J, Wallace L, et al. Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 1995; 345: 1406.
6. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.